Carbidopa for the Treatment of Excessive Blood Pressure Variability
Status:
Completed
Trial end date:
2019-05-10
Target enrollment:
Participant gender:
Summary
The overall study objectives are to determine whether carbidopa (Lodosyn®) is safe and well
tolerated and to assess whether it can inhibit catecholamine-induced paroxysmal hypertension
and normalize or reduce the exaggerated blood pressure variability in patients with familial
dysautonomia (FD, also called hereditary sensory and autonomic neuropathy type III or
Riley-Day syndrome). Funding Source- FDA OOPD.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health